Koki Mori
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Koki Mori has a total of 24 co-authors. Here are the top co-authors by number of shared publications:
Mitsuyo Yoshida
Nursing Department, Ogaki Municipal Hospital
3 shared publications- Eiseki Usami
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki, Gifu, Japan
2 shared publications Kenji Tomita
Department of Psychiatric Neurology, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan
2 shared publications- Michio Kimura
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan
2 shared publications Mitsuhiro Nakamura
Laboratory of Drug Informatics, Gifu Pharmaceutical University, Ogaki-shi, Gifu, Japan
2 shared publicationsTomoaki Yoshimura
Department of Pharmacy, Ogaki Municipal Hospital, Ogaki-shi, Gifu, Japan
2 shared publications
Latest Publications
- Open Access
- 31 December 2025
- Published by Korean Society of Sleep Medicine in Sleep Medicine Research
- Vol. 16 (4) , 220-225
Factors Contributing to Increased Fall Risk in Patients Administered Orexin Receptor Antagonists
Background and Objective Orexin receptor antagonists (ORAs) are increasingly used as hypnotic sedatives. Compared to γ-aminobutyric acid receptor agonists, ORAs lack muscle-relaxant properties and are associated with a lower risk of falls. However, falls do occur in small numbers. We aimed to determine factors correlated with fall risk in patients administered ORAs.Methods Data of hospitalized patients administered suvorexant or lemborexant between January 1, 2022 and December 31, 2023 were retrospectively analyzed. Patients already taking medications upon hospitalization and those with unknown height or weight were excluded. Falls were identified through incident reports. Propensity-score matching was conducted based on demographics and clinical background, followed by statistical analysis. Logistic regression was applied to factors with p<0.2.Results Of 2,348 patients, 1,324 were eligible for analysis. After propensity-score matching, 66 patients were in the falls group and 132 in the non-falls group. Antidepressant use was significantly more common in the falls group (p=0.017) than in the non-falls group. Antidepressant use was associated with increased fall risk (odds ratio [OR], 14.40; p=0.016), whereas comorbid depression was protective (OR, 0.04; p=0.022). No significant associations were found for lemborexant use, benzodiazepine use, heart failure, or schizophrenia.Conclusions Antidepressants increase fall risk in ORA users, whereas comorbid depression may prevent falls.
- 31 December 2025
- Published by Korean Society of Sleep Medicine in Sleep Medicine Research
- Vol. 16 (4) , 220-225
Open AccessFactors Contributing to Increased Fall Risk in Patients Administered Orexin Receptor Antagonists
Background and Objective Orexin receptor antagonists (ORAs) are increasingly used as hypnotic sedatives. Compared to γ-aminobutyric acid receptor agonists, ORAs lack muscle-relaxant properties and are associated with a lower risk of falls. However, falls do occur in small numbers. We aimed to determine factors correlated with fall risk in patients administered ORAs.Methods Data of hospitalized patients administered suvorexant or lemborexant between January 1, 2022 and December 31, 2023 were retrospectively analyzed. Patients already taking medications upon hospitalization and those with unknown height or weight were excluded. Falls were identified through incident reports. Propensity-score matching was conducted based on demographics and clinical background, followed by statistical analysis. Logistic regression was applied to factors with p<0.2.Results Of 2,348 patients, 1,324 were eligible for analysis. After propensity-score matching, 66 patients were in the falls group and 132 in the non-falls group. Antidepressant use was significantly more common in the falls group (p=0.017) than in the non-falls group. Antidepressant use was associated with increased fall risk (odds ratio [OR], 14.40; p=0.016), whereas comorbid depression was protective (OR, 0.04; p=0.022). No significant associations were found for lemborexant use, benzodiazepine use, heart failure, or schizophrenia.Conclusions Antidepressants increase fall risk in ORA users, whereas comorbid depression may prevent falls.
- 17 October 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt A) , 120496
Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database
- 17 October 2025
- Published by Elsevier in Journal of Affective Disorders
- Vol. 394 (Pt A) , 120496
Analysis of acute pancreatitis caused by multi-acting receptor-targeted antipsychotics using the Japanese claims database
- Open Access
- 1 July 2025
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 145 (7) , 629-637
Impact of Promotional Activities on Orexin Receptor Antagonists Prescription Rates and Usage of Sleep and Antipsychotic Medications: An Interrupted Time-series Analysis Study
Lemborexant, an orexin receptor antagonist (ORA), was introduced as a safer sleep medication at our hospital, but its prescription rate remained low. To address this issue, promotion of ORAs began in August 2022. This study aimed to evaluate the impact of these activities on the number of patients prescribed lemborexant. And it aimed to evaluate prescription conditions non-benzodiazepine drugs (NBDs) and delirium treatment antipsychotics (DTAs). The study spanned from August 2021 to March 2024, with August 2022 serving as the intervention point. The drugs analyzed included lemborexant, zolpidem and eszopiclone (NBDs), and risperidone and quetiapine (DTAs). Analyzed using interrupted time-series analysis, and assess changes in the number of patients prescribed these medications and the number of patients with abnormal indications. The promotion of ORAs significantly increased lemborexant prescriptions [level change 18 (95% confidence interval 0.07 to 35: p=0.049), slope change 2.7 (0.57 to 4.9: p=0.015)]. Concurrently, prescriptions for NBDs decreased [level change -56 (-86 to -25: p<0.001), slope change -30 (-54 to -5.7: p=0.017)], and the slope change for DTAs with abnormal instructions also decreased [-1.2 (-2.3 to -0.11: p=0.032)]. No significant differences were found for the other items. Promoting ORAs increased its use, and led to a reduction in the prescriptions of NBDs and DTAs with abnormal indications. Although there was no change in patient conditions, given the adverse effects associated with NBDs and DTAs these changes suggest a shift toward safer drug treatment practices.
- 1 July 2025
- Published by Pharmaceutical Society of Japan in YAKUGAKU ZASSHI
- Vol. 145 (7) , 629-637
Open AccessImpact of Promotional Activities on Orexin Receptor Antagonists Prescription Rates and Usage of Sleep and Antipsychotic Medications: An Interrupted Time-series Analysis Study
Lemborexant, an orexin receptor antagonist (ORA), was introduced as a safer sleep medication at our hospital, but its prescription rate remained low. To address this issue, promotion of ORAs began in August 2022. This study aimed to evaluate the impact of these activities on the number of patients prescribed lemborexant. And it aimed to evaluate prescription conditions non-benzodiazepine drugs (NBDs) and delirium treatment antipsychotics (DTAs). The study spanned from August 2021 to March 2024, with August 2022 serving as the intervention point. The drugs analyzed included lemborexant, zolpidem and eszopiclone (NBDs), and risperidone and quetiapine (DTAs). Analyzed using interrupted time-series analysis, and assess changes in the number of patients prescribed these medications and the number of patients with abnormal indications. The promotion of ORAs significantly increased lemborexant prescriptions [level change 18 (95% confidence interval 0.07 to 35: p=0.049), slope change 2.7 (0.57 to 4.9: p=0.015)]. Concurrently, prescriptions for NBDs decreased [level change -56 (-86 to -25: p<0.001), slope change -30 (-54 to -5.7: p=0.017)], and the slope change for DTAs with abnormal instructions also decreased [-1.2 (-2.3 to -0.11: p=0.032)]. No significant differences were found for the other items. Promoting ORAs increased its use, and led to a reduction in the prescriptions of NBDs and DTAs with abnormal indications. Although there was no change in patient conditions, given the adverse effects associated with NBDs and DTAs these changes suggest a shift toward safer drug treatment practices.
- 29 November 2022
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 24 (6) , 44282
Effects of Pharmacist-Led Dementia Care Round Interventions on the Use of Sleep Medications
Pharmacist-led dementia care rounds are an efficient way to correct sleep medication use and can contribute to benzodiazepine discontinuation, which is especially important in the elderly.
- 29 November 2022
- Published by Physicians Postgraduate Press, Inc in The Primary Care Companion For CNS Disorders
- Vol. 24 (6) , 44282
Effects of Pharmacist-Led Dementia Care Round Interventions on the Use of Sleep Medications
Pharmacist-led dementia care rounds are an efficient way to correct sleep medication use and can contribute to benzodiazepine discontinuation, which is especially important in the elderly.
- 5 November 2021
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- p. 1-5
Sleep-Prolonging Effect of Memantine for Short Periods and Low Doses
- 5 November 2021
- Published by Springer Nature in Neuroscience and Behavioral Physiology
- p. 1-5
Sleep-Prolonging Effect of Memantine for Short Periods and Low Doses
- 1 July 2021
- Vol. 76 (7) , 334-337
Intervention of dementia support team pharmacists and its effects for the proper use of rivastigmine
Pharmacist participation in the medical team is expected in dementia care. We investigated the use of rivastigmine, the intervention of pharmacists for its proper use, and its effects.The number of prescription proposals from the dementia care team pharmacist to the doctor was 87, and the number of acceptances was 57. The content of the proposal was 31/52 for additions/changes (number of acceptances/number of proposals), 21/28 for dose increase, 3/4 for discontinuation of administration, 2/2 for usage changes, and 1/1 for others. In increasing the dose, the number of patients who increased the maintenance dose to 18 mg was significantly higher in the group with the intervention of the pharmacist in the dementia care team than in the group without the intervention (3/12 cases vs. 0/24 cases, p = 0.031). The dose of the brought-in drug also significantly increased with pharmacist intervention compared with that in the non-intervention group (7/12 cases vs. 1/24 cases, p <0.001). The pharmacists of the dementia care team often intervened in the proper use of rivastigmine, which was found to be effective when increasing the dose. Thus, we believe that the active participation of pharmacists is necessary in dementia medication.
- 1 July 2021
- Vol. 76 (7) , 334-337
Intervention of dementia support team pharmacists and its effects for the proper use of rivastigmine
Pharmacist participation in the medical team is expected in dementia care. We investigated the use of rivastigmine, the intervention of pharmacists for its proper use, and its effects.The number of prescription proposals from the dementia care team pharmacist to the doctor was 87, and the number of acceptances was 57. The content of the proposal was 31/52 for additions/changes (number of acceptances/number of proposals), 21/28 for dose increase, 3/4 for discontinuation of administration, 2/2 for usage changes, and 1/1 for others. In increasing the dose, the number of patients who increased the maintenance dose to 18 mg was significantly higher in the group with the intervention of the pharmacist in the dementia care team than in the group without the intervention (3/12 cases vs. 0/24 cases, p = 0.031). The dose of the brought-in drug also significantly increased with pharmacist intervention compared with that in the non-intervention group (7/12 cases vs. 1/24 cases, p <0.001). The pharmacists of the dementia care team often intervened in the proper use of rivastigmine, which was found to be effective when increasing the dose. Thus, we believe that the active participation of pharmacists is necessary in dementia medication.
- 1 April 1994
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 200 (2) , 943-950
Identification of Novel cDNAs Encoding Human Kexin-Like Protease, PACE4 Isoforms
- 1 April 1994
- Published by Elsevier in Biochemical and Biophysical Research Communications
- Vol. 200 (2) , 943-950
Identification of Novel cDNAs Encoding Human Kexin-Like Protease, PACE4 Isoforms